Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M.

N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

PMID:
31166681
2.

Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis.

Chen PH, Ho CL, Lin C, Wu YY, Huang TC, Tu YK, Lee CH.

J Clin Med. 2019 May 23;8(5). pii: E737. doi: 10.3390/jcm8050737.

3.

Venetoclax in the treatment of chronic lymphocytic leukemia.

Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, Robak T.

Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25. Review.

PMID:
30969139
4.

The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.

Molica S, Giannarelli D, Mirabelli R, Levato L, Shanafelt TD.

Leuk Lymphoma. 2018 Dec 5:1-6. doi: 10.1080/10428194.2018.1543882. [Epub ahead of print]

PMID:
30516079
5.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

6.

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.

Robak P, Robak T.

Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265. doi: 10.1080/13543784.2017.1384814. Epub 2017 Oct 3. Review.

PMID:
28942659
7.

Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.

King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA.

Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6. Review.

PMID:
28056525
8.

Management of elderly and unfit patients with chronic lymphocytic leukemia.

Mauro FR, Salaroli A, Caputo MD, Colafigli G, Petrucci L, Campanelli M, Ferretti A, Guarini AR, Foà R.

Expert Rev Hematol. 2016 Dec;9(12):1165-1175. Epub 2016 Nov 21. Review.

PMID:
27796157

Supplemental Content

Loading ...
Support Center